Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guardant HealthMEX:GH 13 Receivables Turnover is 2.29 as of Mar. 2026. GuruFocus rates MEX:GH with a GF Score™ of 13/100 and a GF Value™ of MXN1,017.52 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Guardant Health ranks better than 80.2% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Guardant Health's Revenue for the
three
months ended in Mar. 2026 was MXN5,440 Mil. Guardant Health's average Accounts Receivable for the
three
months ended in Mar. 2026 was MXN2,377 Mil.
Hence, Guardant Health's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.29.
Guardant Health (MEX:GH) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Guardant Health Receivables Turnover Related Terms
Guardant Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Guardant Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GH vs LH, DGX, MEDP: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Guardant Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Guardant Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (MEX:GH) has a Receivables Turnover of 2.29 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Guardant Health and its competitors. According to the industry distribution chart, Guardant Health ranks #40 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 19.8%.
Is Guardant Health's Receivables Turnover too high?
Guardant Health's current Receivables Turnover is 2.29. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Guardant Health's value of 2.29 is 57.4% below this industry median. Based on the distribution chart, Guardant Health ranks #40 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Guardant Health has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Receivables Turnover compare to LH and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Guardant Health ranks #40 out of 202 companies for Receivables Turnover. This places Guardant Health in the top 20% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.38. Guardant Health's value of 2.29 is 57.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guardant Health's current Receivables Turnover of 2.29 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Guardant Health and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guardant Health's current Receivables Turnover is 2.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (MEX:GH) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,017.52, compared to a current price of MXN2,590.00 — trading 154.5% above its estimated fair value. The current Receivables Turnover is 2.29 and 57.4% below the Medical Diagnostics & Research industry median of 5.38. Guardant Health's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Guardant Health (MEX:GH), the current Receivables Turnover is 2.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guardant Health (MEX:GH) Overvalued in 2026?
Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued.
The current stock price of MXN2,590.00 is trading 154.5% above its estimated GF Value™ of MXN1,017.52.
GuruFocus considers Guardant Health to be Significantly Overvalued.
Key valuation signals for MEX:GH:
Receivables Turnover: 2.29
GF Value™: MXN1,017.52 vs. price of MXN2,590.00 (154.5% above fair value)
Industry Position: 57.4% below the Medical Diagnostics & Research median (#40 of 202)
No single metric tells the full story. See the MEX:GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
13GF Score
Get the complete analysis for MEX:GH
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GH has been successfully added to your 
